HNSB.F Stock Overview
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.93 |
| 52 Week High | kr5.30 |
| 52 Week Low | kr2.26 |
| Beta | 1.26 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -82.75% |
| 5 Year Change | -87.23% |
| Change since IPO | -36.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSB.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how HNSB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HNSB.F performed against the US Market.
Price Volatility
| HNSB.F volatility | |
|---|---|
| HNSB.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HNSB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HNSB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 166 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSB.F fundamental statistics | |
|---|---|
| Market cap | US$147.51m |
| Earnings (TTM) | -US$77.29m |
| Revenue (TTM) | US$15.17m |
9.7x
P/S Ratio-1.9x
P/E RatioIs HNSB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSB.F income statement (TTM) | |
|---|---|
| Revenue | kr165.88m |
| Cost of Revenue | kr71.66m |
| Gross Profit | kr94.23m |
| Other Expenses | kr939.10m |
| Earnings | -kr844.88m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | -15.35 |
| Gross Margin | 56.80% |
| Net Profit Margin | -509.33% |
| Debt/Equity Ratio | -247.8% |
How did HNSB.F perform over the long term?
See historical performance and comparison